Perspective Therapeutics, based in Seattle, is a biotechnology company focused on developing radiopharmaceuticals for cancer treatment using the alpha-emitting isotope 212Pb. Their programs for melanoma and neuroendocrine tumors are in Phase I/IIa trials.
Juan Graham bought 33,333 shares of CATX on 28 March at $2.25 per share, worth a total of $75K. They now own 35,354 CATX shares, or a 1649% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
